Discussion  by unknown




Sof another primary tumor site or metastatic spread
beyond the mediastinum
Pulmonary function acceptable for surgery according to
institutional criteria
Laboratory criteria (within 30 days of enrollment):
Absolute neutrophil count 1500/mL
Platelet count 100,000
Total bilirubin and aspartate aminotransferase/alanine
aminotransferase1.5 times the institutional upper
limit of normal
Creatinine clearance 50 mL/min (calculated using
institutional standard)Exclusion Criteria
Patients thought to be unable to medically tolerate surgi-
cal resection as assessed at the initial presentation
Hypersensitivity to cisplatin and/or etoposide
Patients with radiographic evidence of stage IVA thy-
moma (pleural or pericardial disease noncontiguous
with the primary tumor site)
Pretreatment biopsy showing WHO type A thymoma
when reviewed by institutional pathologists, un-
less obvious great vessel invasion and/or encircle-
ment is present on the CT scan; it is understood
that a WHO subtype might not be able to be
assigned on the basis of the biopsy specimen in
all cases
Previous radiotherapy to the chest that would preclude
the administration of radiation using 3-dimensional
conformal or intensity-modulated radiotherapy plan-
ning
Significant medical or psychiatric illness that would
interfere with patient compliance
Patients whose 3-dimensional radiotherapy plan cannot
meet the dose–volume constraint
Patients receiving other investigational drugs
Pregnant women or women of childbearing potential
(women are not considered of childbearing potential
if they are2 years postmenopausal and/or surgically
sterile) who refuse to use effective contraception; will
be determined on the judgment of the institutional
principal investigators or designated associates
Failure to meet inclusion criteriaAPPENDIX 2. INDUCTION REGIMEN
Cisplatin was administered by continuous intravenous
infusion for 1 hour on days 1, 8, 29, and 36 at a dose of
50 mg/m2. The patients were hydrated both before and afterThe Journal of Thoracic and Cardiovascular Surgecisplatin dosing with mannitol and saline. The use of
colony-stimulating factors was prohibited. Etoposide was
administered by continuous intravenous infusion for 1
hour on days 1 to 5 and 29 to 33 at a dose of 50 mg/m2.
Dosage modifications, including reductions and delays,
were incorporated into the protocol for hematologic
toxicity, if the creatinine clearance decreased to<50 mL/
min, and/or grade 3 or 4 nonhematologic toxicity.
Preoperative radiotherapy began within 24 hours of
chemotherapy initiation using either a 3-dimensional
conformal–or intensity-modulated radiotherapy–based
plan. The radiation dose was 4000 to 4500 cGy at 180 to
200 cGy/fraction (weeks 1-5; Monday through Friday).
The treatment target included the entire thymus and the
gross tumor, with a 2 to 2.5-cm margin. To minimize
toxicity, dose–volume constraints were incorporated into
the radiation plan for the lungs, esophagus, heart, and spinal
cord. Radiotherapy interruptions were permitted for febrile
neutropenia, grade 4 mucositis or esophagitis, and grade
3-4 pulmonary toxicity.
Postoperative Treatment
Patients undergoing adjuvant chemotherapy alone
received cisplatin by continuous intravenous infusion for
1 hour on days 1 to 3 and 29 to 31 at a daily dose of
33 mg/m2. Patients were hydrated both before and after
cisplatin dosing with mannitol and saline. Etoposide was
administered by continuous intravenous infusion for 1
hour on days 1 to 3 and 29 to 31 at a dose of 100 mg/m2.
Patients undergoing adjuvant chemoradiotherapy (patients
with incomplete resection) received the same treatment
protocol used in the preoperative setting, except that
only an additional 2000 to 2500 cGy of radiation (180 to
200 cGy/fraction; ending during the third treatment week)
was administered to the sites of residual disease. In these
cases, the chemotherapy dose for the second postoperative
cycle was increased to the level administered in the
absence of radiotherapy (cisplatin 33 mg/m2 and etoposide
100 mg/m2 on days 29-31).Discussion
Dr Frank C. Detterbeck (New Haven, Conn). Bob, nice
presentation. I want to thank you for pulling this off. This was
really Bob’s trial that he initiated, and I think to pull off a
multicenter trial with multiple institutions and a rare disease
such as thymoma is really an accomplishment, and I think that is
great. There really are not all that many prospective series out
there. I think that is 1 of the strengths of this study—it is a
multicenter trial, and it is prospective. I think another major
strength is that the patients are really quite well characterized by
the radiographic findings. I think all too often we are limited by
reading reports. One walks away from the report, saying, ‘‘well,
that is interesting, but I really do not have a strong clue about
what these patients really looked like and whether a patient I amry c January 2014
Korst et al General Thoracic Surgery
G
T
Sseeing is going to be similar to what was reported.’’ Thus, I think
those are the real strengths of what you reported, and, certainly, the
lack of any recurrence in those who underwent complete resection
is pretty exciting.
My first question is about the choice of chemoradiotherapy
versus chemotherapy. I did a brief review of the studies that
have been published on induction chemotherapy, certainly patients
who were not quite as well characterized but had stage III
thymoma or thymic carcinoma, and I think that your complete
resection rate was pretty similar, 77% versus 75%. Your survival
was pretty similar at 5 years, 71% versus 74%. However, your
CPR rate was lower, 0% versus 18% in the other studies, and the
partial response rate was lower also, about 46% versus 89%. So
I am not necessarily seeing a benefit as I would have expected
from chemoradiotherapy, and I am wondering about your thoughts
about that.
Dr Robert J. Korst. Thank you, Dr Detterbeck.
We had the same impression as well. There have been a couple
of CPRs in at least 1 of the other prospective clinical trials of this
disease, but we did not see any, despite the addition of another
locally acting agent. We did, however, have 5 near CPRs in the
patients with thymic carcinoma. I think from a toxicity standpoint,
we are in the ballpark with chemotherapy alone. I do not think our
study had significantly more toxicity than some of the other
published data. The studies, however, were drastically different
in terms of the stages included and other inclusion criteria. The
patients had been deemed unresectable in the other 2 prospective
studies, but that is a highly subjective term. In addition to that,
the chemotherapy agents were different. One of the studies was
actually a chemotherapy and prednisone study. Thus, it is really
difficult to make comparisons.What we tried to dowith the present
study was to try and make some of these factors as objective as
possible, such that in the future, when other studies are done, the
data can be compared.
It is hard to say I am going to change my practice because of a
22-patient prospective, single-arm trial, but it is all we have in
thymoma. I have always treated with preoperative chemotherapy
for locally advanced thymoma; however, the data for the thymic
carcinoma are intriguing. Of the 7 patients, 4 had a near CPR. It
is also the patients with thymic carcinoma who also had the
most significant radiographic response. Therefore, if I had a
patient with thymic carcinoma who presented to me and met these
criteria, I would probably treat them with chemoradiotherapy up
front.
Dr Detterbeck.My next question is where do we go from here?
This is an intriguing trial, 20 patients. It is slightly more difficult to
really know for sure whether it is chemoradiotherapy versus
chemotherapy, et cetera, et cetera, what is really the way to go
and how do we get more science behind what we should be doing
as we move forward.
Dr Korst.Well, what we really need to do is band together and
start doing trials in this rare disease. I can tell you that I shopped
this trial around to anyone who would listen 5 years ago, and the
response was always similar, which was, ‘‘We are going to see 2
patients this year. It is really not worth our while to get this through
our institutional review board.’’ We have to change that, and if we
can change that, we can start investigating all types of questions for
these patients.The Journal of Thoracic and CDr Scott J. Swanson (Boston, Mass). I really enjoyed it, Rob.
Without seeing the scans, it is hard for us to know what you
were looking at. How comfortable are you that these patients
had unresectable disease before treatment and is there some other
minimally invasive method we should use to ensure that? Because
if 4 or 5 of these patients had resectable disease before this
treatment, perhaps they did not need this intensive therapy up
front.
DrKorst.Well, that is clearly a good point, and I will be the first
to tell you that unresectability was not an inclusion criterion. There
were some patients who, if you looked at the scan, you would say,
‘‘I could probably take that out,’’ and then there actually were some
patients who had terrible disease. The remainder of the patients
were all kind of on that fence. One third of the patients had
clear-cut great vessel or organ invasion, indicating an intraluminal
tumor. It is hard to make comparisons in this disease because my
‘‘unresectable’’ might not be your ‘‘unresectable.’’
Dr Swanson. I have 1 last follow-up question. Carcinoma
sounds clear and clear-cut invasion sounds clear. If you have a
patient you are not so sure about now but who fits these criteria,
would you give them the induction therapy or would you try to
resect them, you know, off the protocol?
Dr Korst. If I was treating off the protocol, I think what I would
do is probably treat with preoperative chemotherapy for patients
with marginally resectable disease at this point, unless they were
a patient with carcinoma or perhaps B3, for whom I would use
chemoradiotherapy.
Dr Swanson. So nobody progresses. You do not lose the ability
to resect anybody.
Dr Korst. No one progressed.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). I have just a
comment to Scott’s question. When you consider the survival
curves of thymoma and you consider the ones that we resect that
recur later, that was sort of the target we were looking at, the
high risk of recurrent tumors or a high risk of incomplete resection.
So, the patients who you see clearly do not have resectable disease
and ‘‘let us try and treat them and see whether we can make them
resectable’’ were not really the target for this trial. It was more the
high-risk larger tumors in general, but not necessarily just large,
and then showing invasive or aggressive features, to see whether
we could improve on that. The pleasant surprise was how well
the thymic carcinomas behave with this induction therapy.
So, those were 2 important nuances.
Dr Jacques-Pierre Fontaine (Tampa, Fla).Of the 23% of your
patients who did not undergo an R0 resection, what percentage
were able to receive postoperative radiotherapy for those positive
margins, seeing that they all had already received 4000 to 4500
cGy preoperatively? As a follow-up comment, if your trial
does not show an increased rate of R0 resectability or a change
in survival compared with previous series, albeit not truly
comparable, why not simply give them induction chemotherapy
only, resect, and treat your R1 and R2 resections with higher
doses of uninterrupted postoperative radiotherapy, which would
be more effective than lower doses or interrupted doses of
radiation?
Dr Korst. Of the patients who did not undergo an R0 resection,
1 underwent debulking and died postoperatively, but the other
4 were treated.ardiovascular Surgery c Volume 147, Number 1 45
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SDr Fontaine. So, they were able to undergo radiotherapy
despite the initial radiation?
Dr Korst. They were able to be treated. Again, it is a matter of
philosophy. The purpose of the trial was to try to enhance our rate
of complete resection by adding another local modality. It is
unfortunate that the trials are really not comparable. The other
trials excluded patients with thymic carcinoma. One third of our
patients had carcinoma. You just cannot compare the patients.
Dr Dirk Van Raemdonck (Leuven, Belgium). With regard to
your pretreatment staging, did you do thoracoscopy in any of these
patients or in all patients to exclude stage IVA disease?
Dr Korst. No. It was all done radiographically. A single patient
was found to have stage IVA disease once they had undergone
resection. Also, we had 2 patients who had stage IVB because of
nodal disease.
Dr Joshua R. Sonett (New York, NY). It was a great endeavor
and great project, with results that I think will be extremely46 The Journal of Thoracic and Cardiovascular Surgehelpful. One question that I have encountered is trying to sort
out the large thymomas that will not respond to induction
therapy and, thus, should avoid induction. Thus, using pathol-
ogy or molecular studies, we need to separate out who should
receive therapy for thymoma. I have had a number of patients
with very large thymomas that had very disappointing results
from induction chemotherapy. I am wondering whether you
could glean anything from your data that indicates which of
those thymomas responded and which did not, because if they
are not going to respond, clearly, the whole debate about
whether to go straight to surgery or give them induction is
less relevant.
Dr Korst. Most type A thymomas can be resected. I think
the WHO histologic type plays a large role in the decision.
However, the carcinoma or B3 cases, I think those are
the ones for which one must entertain the idea of induction
therapy.ry c January 2014
